Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Faivre-Finn, C, Snee, M, Ashcroft, L et al. (17 more authors) (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology, 18 (8). pp. 1116-1125. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Faivre-Finn, C
  • Snee, M
  • Ashcroft, L
  • Appel, W
  • Barlesi, F
  • Bhatnagar, A
  • Bezjak, A
  • Cardenal, F
  • Fournel, P
  • Harden, S
  • Pechoux, CL
  • McMenemin, R
  • Mohammed, N
  • O'Brien, M
  • Pantarotto, J
  • Surmont, V
  • Meerbeeck, JPV
  • Woll, PJ
  • Lorigan, P
  • Blackhall, F
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license.
Dates:
  • Published: August 2017
  • Published (online): 20 June 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 20 Jun 2017 12:44
Last Modified: 26 Jul 2018 08:50
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S1470-2045(17)30318-2

Share / Export

Statistics